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The human immunodeficiency virus type 1 (HIV-1) RNA genome is flanked by a repeated sequence (R) that
is required for HIV-1 replication. The first 57 nucleotides of R form a stable stem-loop structure called the
transactivation response element (TAR) that can interact with the virally encoded transcription activator
protein, Tat, to promote high levels of gene expression. Recently, we demonstrated that TAR is also important
for efficient HIV-1 reverse transcription, since HIV-1 mutated in the upper stem-loop of TAR showed a reduced
ability both to initiate and to complete reverse transcription. We have analyzed a series of HIV-1 mutant
viruses to better defined the structural or sequence elements required for natural endogenous reverse tran-
scription and packaging of virion RNA. Our results indicate that the requirement for TAR in reverse tran-
scription is conformation dependent, since mutants with mutations that alter the upper stem-loop orientation
are defective for reverse transcription initiation and have minor defects in RNA packaging. In contrast, TAR
mutations that allowed the formation of alternative upper stem-loop structure greatly reduced RNA packaging
but did not affect reverse transcription efficiency. These results are consistent with direct involvement of the
upper stem-loop structure in packaging of genomic RNA and suggest that the TAR RNA stem-loop from
nucleotide 118 to 142 interacts with other components of the reverse transcription initiation complex to
promote efficient reverse transcription.
The human immunodeficiency virus type 1 (HIV-1) RNA
genome can form numerous RNA structures, many of which
regulate virus replication. Viral RNA structures are required
for many processes, including transcription by RNA polymer-
ase II, polyadenylation of viral mRNA, transport of singly
spliced and unspliced viral mRNA, viral genomic RNA dimer-
ization and packaging, and reverse transcription. For example,
the TAR element, which comprises the first 57 nucleotides (nt)
of the viral transcript, can form a stable stem-loop structure.
The Tat protein and cellular kinases, which are recruited by
Tat, can bind to the TAR stem-loop to enable efficient tran-
scription by RNA polymerase II (for reviews, see references
12a and 24a). Another example is the HIV-1 RNA packaging
signal, which includes a series of RNA stem-loop structures
(designated SL1, SL3, and SL4) which flank the 59 major splice
donor site (3, 9, 19, 27) and bind to the nucleocapsid domain
of the pr55 Gag protein to promote packaging of unspliced
HIV-1 transcripts into virions (2, 5, 12, 29). Another regulatory
viral RNA structure is formed by sequences flanking the
primer binding site in conjunction with cellular tRNA3
Lys. In-
teractions between an A-rich loop upstream of the virus primer
binding site and the anticodon loop of tRNA3
Lys are reported to
be required for the formation of an efficient reverse transcrip-
tion initiation complex (21, 23, 24).
It has long been appreciated that a single viral RNA struc-
ture can have effects on multiple steps in the replication cycle.
The TAR element, for example, has also been shown to reduce
translation of viral mRNA both in Xenopus oocyte microinjec-
tion assays and in cell-free translation systems (6, 31). Genetic
analysis of TAR showed that maintenance of the TAR stem-
loop structure and the primary sequence of the loop were
required for inhibition of HIV-1 translation. Mutations that
disrupted the TAR lower stem increased translation efficiency,
while compensatory mutations that restored stem base pairing
also restored TAR-mediated inhibition of translation. More
recently, TAR has been implicated in the encapsidation of
virus genomic RNA (8, 11, 20, 28). Viruses lacking the TAR
element or carrying mutations that disrupted the lower portion
of the TAR stem structure reduced RNA encapsidation, and
some, but not all, of these mutations reduced reverse transcrip-
tion efficiency. As with translation, compensatory mutations
that restored TAR base pairing also restored RNA encapsida-
tion, indicating that TAR structure, but not primary sequence,
is required for efficient RNA encapsidation. How TAR acts in
packaging is not known, but evidence that distinct pools of
genomic RNA are packaged into virions makes it plausible that
TAR-mediated inhibition of translation may contribute to the
selection of nontranslated genomic RNA by Gag in the pack-
aging process (26). In a previous study, we showed that muta-
tions within the upper TAR stem-loop structure greatly re-
duced reverse transcription efficiency, but no defect in RNA
encapsidation was observed (18). In the present study, we
constructed further HIV-1 TAR mutations and determined
their effects on viral reverse transcription and RNA packaging.
Our results suggest that TAR’s role in reverse transcription is
dependent on the conformation of the upper stem-loop struc-
ture, from nucleotides 118 to 142, and that this region of
TAR also supports RNA encapsidation.
* Corresponding author. Mailing address: Sir Albert Sakzewski Vi-
rus Research Centre, Royal Children’s Hospital, Herston Rd., Her-
ston, Queensland, Australia 4029. Phone: 617-3636-1679. Fax: 617-
3636-1401. E-mail. d.harrich@mailbox.uq.edu.au.
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MATERIALS AND METHODS
Plasmids and sequences. All HIV-1 sequence notations take the transcription
start site (GGG of TAR) as 11. The HIV-1 infectious molecular construct
pBRDH2-neo and procedures used to introduce TAR mutations into this con-
struct have been previously described (15). Briefly, a plasmid containing HIV-1
sequences from position 2160 to 1988 was mutagenized using the QuickChange
mutagenesis system and oligonucleotides that included the desired mutations in
both DNA strands. The mutations were confirmed by DNA sequence determi-
nation using the Sequenase system (Amersham Pharmacia Biotec) and ligated
into pBRDH2-neo. The runoff RNA used as an internal control in quantitative
reverse transcriptase PCR (RT-PCR) analysis was synthesized from a pGEM3z
(Promega Australia Pty. Ltd.) construct containing HIV-1 sequences from po-
sition 222 to 1553 with an internal deletion from 180 to 1151. The construct
was linearized with EcoRI and used as the template for in vitro transcription by
SP6 RNA polymerase. The runoff RNA used for quantitative RNA protection
assays was synthesized from a pGem4z (Promega Australia Pty. Ltd.) construct
containing HIV-1 sequences from position 1113 to 1553. This construct was
linearized with EcoRI and used as the template for in vitro synthesis of radio-
labeled RNA riboprobe using [32P]CTP (400 Ci/mmol) (ICN Pharmaceuticals)
and T7 RNA polymerase (Promega Australia Pty. Ltd.). All in vitro transcripts
were purified from 5% polyacrylamide gels before use.
Cell lines, viruses, and infections. All cells were incubated at 37°C in a
humidified 5% CO2 atmosphere. The method by which stable cell lines were
generated is described in detail elsewhere (15). Briefly, 293 cells were transfected
with the mutated pBRDH2-neo construct, allowed to recover for 48 h, and then
serially diluted in Iscove’s modified Dulbecco minimal essential medium
(IMDM) supplemented with 1% penicillin-streptomycin, 1 mM Glutamax, 5%
newborn calf serum, and 2% fetal bovine serum (complete IMDM) plus 800 mg
of G418 sulfate (Life Technologies) per ml. Individual cell foci were isolated and
expanded, and supernatant from each culture was assayed for HIV-1 p24 antigen
(Ag). Cell lines that produced p24 Ag were further characterized.
Virus stocks were produced and assayed as previously described (32). Briefly,
293 cell lines stably transfected with either wild-type or TAR mutant virus were
grown in 100-mm-diameter tissue culture dishes in complete IMDM supple-
mented with 500 mg of G418 sulfate per ml. When the cells reached 50%
confluency, the supernatant was replaced with complete IMDM lacking G418
sulfate, and the plates were incubated for a further 18 to 24 h. The medium was
collected, filtered through a 0.45-mm-pore-size PES membrane, and stored in
aliquots at 80°C. The virus stocks were assayed for HIV-1 p24 Ag using a
commercial enzyme-linked immunosorbent assay (NEN Life Science Products)
and for RT activity using the RT Detect Assay (Roche Diagnostics Australia Pty.
Ltd.).
To infect Jurkat cells, filtered culture supernatant containing 90 mU of RT
activity was adjusted to 10 ml with cell-conditioned culture medium and incu-
bated with 2 3 106 cells for 2 h with gentle rotation. Mock infections were carried
out with wild-type virus inactivated by incubation at 60°C for 20 min. The
infected Jurkat cells were washed three times with culture medium to remove
residual virus and incubated in RPMI 1640 medium supplemented with 1%
penicillin-streptomycin, 1 mM Glutamax, and 10% fetal bovine serum. The cells
were passaged twice weekly and assayed for p24 Ag by enzyme-linked immu-
nosorbent assay as described above.
PCR and RT-PCR assays. Chromosomal DNA was isolated from 293 cell lines
using DNAzol (Life Technologies). The long terminal repeats (LTRs) of TAR
mutant viruses were amplified by 30 cycles of PCR (95, 55, and 72°C for 1 min
each) using purified chromosomal DNA (500 ng) as a template, 1.25 U of
Platinum Taq DNA polymerase (Life Technologies), and 50 ng of each of the
following oligonucleotide pairs: 59 LTR, 2436/2415 (59-CCC AAA CAA GAC
AAG AGA TTG A, sense) and 1242/1219 (59-CCT GCG TCG AGA GAG
CTC CTC TGG, antisense); 39 LTR, 18605/18625 (59-GCA GCT TTA GAT
ATT AGC CAC, sense) and 19282/19258 (59-CTG CTA GAG ATT TTT CCA
CAC TGA C, antisense). The 678- and 677-bp PCR products amplified from the
59 and 39 LTRs, respectively, were ligated into pGemTeasy (Promega) and
analyzed by DNA sequencing.
Quantitative RT-PCR was carried out on virion-associated RNA isolated from
pelleted virus particles. DNase I-treated stocks of wild-type or TAR mutant virus
were subjected to centrifugation through a 20% sucrose cushion at 120,000 3 g
for 90 min at 4°C and resuspended in serum-free IMDM. The viral suspensions
were assayed for p24 Ag and RT activity as described above. Equal amounts of
p24 Ag (100 ng) were solubilized with Trizol (Life Technologies) according to
the manufacturer’s recommendations, and 5 ng of internally deleted HIV-1
internal control RNA was added to monitor RNA recovery and in vitro reverse
transcription efficiency. Nucleic acids were precipitated overnight and recovered
by centrifugation at 15,000 3 g at 28°C for 1 h. The visible pellets were rinsed
FIG. 1. RNA stem-loop structures and stem energies of wild-type and mu-
tated TAR RNA sequences. TAR mutations are shown as follows: 1, 3-nt dele-
tion from position 122 to 124 (TAR1); 2, 6-nt deletion from position 119 to
124 (TAR2); 3, combined 3-nt deletion from position 122 to 124 and com-
pensatory 3-nt insertion of UCU at position 139 (TAR3); 4, three nucleotide
substitutions at positions 115, 116, and 118 (TAR4); 5, four nucleotide sub-
stitutions at positions 118, 119, 121, and 139 (TAR5); and 6, six nucleotide
substitutions, at nt 118, 119, 121, 139, 141, and 142, that maintained the
stem-loop structure (TAR6). RNA stem-loop structure energies (DG), shown in
kilocalories per mole, were predicted using M-fold version 3.0 (copyright 1996 by
M. Zuker; http://mfold.burnet.edu.au).
TABLE 1. Analysis of partially purified virusa
Virusb p24 Ag(ng/ml)c
RT activity
(nU/ml)d
p24
Ag/RTe
Virus replicationf
(%)
TAR1 115 3.0 38.3 Negative
TAR2 92 2.1 43.8 Negative
TAR3 103 2.4 42.9 Negative
TAR4 257 7.8 32.9 3
TAR5 1,212 26.9 45.0 5
TAR6 261 8.2 31.7 100
Wild type 714 15.8 45.2 100
a The results are representative of those from three independent experiments.
b The TAR RNA sequence is shown in Fig. 1.
c Concentration of p24 Ag measured in virus pelleted through a 20% sucrose
cushion.
d RT activity of virus pelleted through a 20% sucrose cushion.
e Absolute value of p24 Ag concentration divided by RT activity.
f Peak p24 Ag concentration in culture supernatant relative to the wild-type
level.
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with 70% ethanol and dissolved in 30 ml of water. Virion RNA was reverse
transcribed using C-Therm DNA polymerase (Roche Diagnostics Australia Pty.
Ltd.) according to the manufacturer’s instructions in duplicate reaction mixtures
containing 10 ml of viral RNA and 50 ng of either first-strand primer B (1412/
1387; 59-GAC TGC GAA TCG TTC TAG CTC CCT GC, antisense) or first-
strand primer A (1288/1267; 59-CAG TCG CCG CCC CTC GCC TCT TG,
antisense). The RT reaction mixtures were serially diluted and assayed for the
internal control RNA by 27 cycles of PCR as described above with oligonucle-
otide primers complementary to the polylinker region of pGem3z (59-GGG
AGA CAA GCT TGC ATG CCT G, sense) and to HIV-1 sequences from
position 165 to 146 (59-AAG CAG TGG GTT CCC TAG TTA G, antisense).
The HIV-1-specific primer was radiolabeled using T4 polynucleotide kinase and
[g-32P]ATP. The reaction mixtures were normalized according to internal con-
trol cDNA concentrations and assayed for HIV-1 cDNA by 30 cycles of PCR as
described above with a radiolabeled HIV-1-specific oligonucleotide, primer 196/
1118 (59-CAA GTA GTG TGT GCC CGT CTG TT, sense), and an unlabeled
primer, 1182/1158 (59-CTG CTA GAG ATT TTT CCA CAC TGA C, anti-
sense). The PCR products were then separated on 5% polyacrylamide (19:1
acrylamide/bisacrylamide ratio) gels and quantified by PhosphorImager (Molec-
ular Dynamics) analysis using PCR standard curves generated from plasmids
containing the target sequences. All PCRs were performed in the linear range of
the assay.
RNA protection assay. RNA protection assays were performed using an
RPAII kit (Ambion) according to the manufacturer’s instructions. Briefly,
DNase I-treated sucrose cushion-purified virus containing 100 ng of p24 Ag was
solubilized along with 10 mg of purified yeast RNA and a radiolabeled RNA
riboprobe (Promega Australia Pty. Ltd.) using Trizol reagent (Life Technolo-
gies). The RNA mixtures were incubated in the hybridization solution provided
with the kit at 46°C for 16 h and digested with a combination of RNase T1 and
RNase A. The digested RNAs were precipitated with ethanol and centrifuged at
12,000 3 g at 4°C, and the pellets were resuspended in the RNA loading dye
provided. The digested RNAs were separated on denaturing (7.3 M urea) 5%
polyacrylamide gels and visualized and quantitated by PhosphorImager (Molec-
ular Dynamics) analysis.
RT assays. Wild-type and TAR mutant virus stocks were assayed for total RT
activity on a synthetic homopolymer template in the presence of detergent using
the RT Detect Assay (Roche Diagnostics) according to the manufacturer’s in-
structions. Aliquots of virus (typically 1.0 mU of RT activity) were supplemented
with 10 mM MgCl2 and incubated for 30 min at 37°C with 100 U of DNase I in
a final volume of 200 ml of IMDM. Reverse transcription was terminated in half
of the DNase I-treated virus stock by the addition of 150 ml of stop solution (10
mM Tris-HCl [pH 7.4], 10 mM EDTA, 20 mg of sheared salmon sperm DNA per
ml, and 50 mg of proteinase K per ml) followed by incubation at 37°C for 10 min
and then boiling for 10 min. The remaining 100 ml was supplemented with 200
FIG. 2. Representative NERT assay of wild-type and TAR mutant viruses. (A) negative strong-stop DNA detected by PCR in NERT reactions with TAR1, TAR2,
TAR3, TAR4, TAR5, TAR5, TAR6, or wild-type virus (lanes 1 to 7, respectively) or mock supernatant (lane 8). (B) PhosphorImager analysis of the PCR shown in
panel A; DNA copy number is indicated. (C) PCR standard curve generated using an HIV-1 proviral plasmid. (D) PhosphorImager analysis of the gel shown in panel
C; r2 5 0.996.
FIG. 3. RT-PCR strategy. HIV-1 genomic RNA (A) was isolated from virus containing 100 ng of p24 Ag along with added synthetic internal control RNA (B)
containing plasmid sequence (dotted line) and HIV-1 sequences from position 222 to 1517, except for an internal deletion from 180 to 1151. The isolated RNA was
reverse transcribed in separate reactions using the first-strand primers shown (solid arrows). Primer A can anneal to either spliced or unspliced HIV-1 RNA, while
primer B can anneal to unspliced but not to spliced HIV-1 RNA; both primers can anneal to internal control RNA. HIV-1 and internal control cDNAs were detected
by PCR using the primers shown (dotted arrows). PBS, primer binding site.
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mM deoxynucleoside triphosphates and incubated at 37°C for 90 min, and then
the reaction was terminated as described above. The stopped reaction mixtures
were centrifuged briefly at 14,000 3 g, and 10 ml of each was assayed for
negative-strand strong-stop DNA by 34 cycles of PCR (65°C for 2 min and 93°C
for 1 min) using the HIV-1-specific oligonucleotide primers 196/1118 (radio-
labeled) and 1158/1182 in the presence of 3.5 mM MgCl2 to compensate for
EDTA present in the stop mix. PCR standard curves were generated by ampli-
fying serial dilutions of an HIV-1 proviral plasmid, and all PCRs were performed
in the linear range of the assay.
RESULTS
Isolation and characterization of cell lines making wild-type
and TAR mutant HIV-1. In a previous study we identified
HIV-1 viruses with mutated TAR RNA sequences which sup-
ported transactivation by Tat and high levels of gene expres-
sion but did not support efficient virus replication (18). Our
original analysis showed that these viruses were defective for
reverse transcription. However, two recent reports have shown
that mutations of the HIV-1 lower stem-loop resulted in de-
creased packaging of virus genomic RNA and supported pack-
aging of HIV-1 spliced RNA transcripts (8, 11). Our original
study found either minor or no packaging defects but did not
exclude the possibility that packaging of spliced RNA tran-
scripts was responsible for the observed reverse transcription
defects.
The following mutations were introduced into the TAR
RNA upper stem-loop structure in the HIV-1 proviral con-
struct pBRDH2-neo: a six-base deletion of nt 119 to 124
(TAR2), a three-base deletion of nt 122 to 124 in combina-
tion with a compensatory UCU insertion (TAR3), and a three-
base substitution at nt 115, 116, and 118 (TAR4) (Fig. 1).
Each mutated proviral DNA was transfected into 293 cells, and
stable cell lines producing each TAR mutant virus were se-
lected and characterized as previously described (15). In addi-
tion, three stable cell lines which have been described else-
where (15) were used to produce viruses carrying the following
TAR RNA mutations: a three-base deletion from nt 122 to
124 (TAR1); a four-base substitution at nt 118, 119, 121 and
139 (TAR5); and a six-base substitution mutation, nt 118,
FIG. 4. RT-PCR analysis of virion RNA levels. Virion RNA was isolated
from partially purified TAR1, TAR2, TAR3, TAR4, TAR5, TAR6, and wild-
type virus (lanes 1 to 7 respectively), to which internal control RNA had been
added. The isolated RNAs were reverse transcribed in either the presence or
absence (not shown) of C-Therm DNA polymerase and first-strand primer A (A
and C) or first-strand primer B (B and D). PCR to detect HIV-1 cDNA (A and
B) or internal control cDNA (C and D) was performed using the primers shown
in Fig. 3. The PCR products were separated by polyacrylamide gel electrophore-
sis and analyzed with a Molecular Dynamics PhosphorImager. The copy numbers
shown for HIV-1 cDNA (A and B) are normalized to internal control cDNA
copy numbers (C and D). The correlation coefficients (r2) of standard curves
generated with plasmid DNA were 0.992 for HIV-1-specific primers and 0.997
for internal control-specific primers (data not shown). The data shown are
representative of those from three similar replicate experiments using different
virus stocks.
FIG. 5. RNA protection assay of cellular and virion RNAs. Total cellular
RNA was isolated from stable 293 cell lines producing TAR4 (lane 2), TAR5
(lane 1), and wild-type (lane 3) HIV-1. Ten micrograms of total cellular RNA or
virion RNA isolated from TAR4 (lane 5), TAR5 (lane 4), and wild-type (lane 6)
virus containing 100 ng of p24 Ag was annealed to excess radiolabeled RNA
probe. The same RNA probe was also incubated with 10 mg of yeast RNA (lanes
7 and 8). The annealed RNA mixtures were digested with RNase T1 and RNase
A. Intact probe is shown (lane 8 and dotted arrow). Protected fragments corre-
sponding to unspliced (top arrow, 363 nt) or spliced (bottom arrow, 189 nt)
HIV-1 RNA are indicated.
FIG. 6. Relative reverse transcription efficiencies of wild-type and TAR mu-
tant viruses. The reverse transcription efficiency of each virus was calculated as
the percentage of wild-type negative strong-stop DNA synthesis measured by
NERT assay divided by the percentage of wild-type virion RNA detected by
RT-PCR (values were averaged over two different first-strand primers). Relative
reverse transcription efficiencies of TAR1, TAR2, TAR3, TAR4, TAR5, TAR6,
and wild-type viruses (lanes 1 to 7, respectively) are shown.
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FIG. 7. Computer model of potential HIV-1 RNA secondary structures in the presences of stem-destabilizing clustered mutations. (A) HIV-1 RNA secondary
structure predicted from the wild-type HIV-1 HXB2 sequence from position 11 to 1359 using M-fold version 3.0. Stem-loop structures corresponding to TAR, pA,
SL1, SL2, SL3, and SL4 as well as the primer binding site (PBS) are indicated. (B) Predicted secondary structure of TAR RNA (positions 11 to 157) showing the
clustered mutation Xho110 (10) indicated by red letters. HIV-1 nt 1274 to 1284 (shown in blue) can base pair to sequences in Xho110. A dotted arrow indicates
a shift by cytidine 1243 (green) to base pair with guanine 1272 (green). (C) The new secondary structure maintains TAR and pA stem-loop structures (not shown),
SL3, and SL4 but eliminates SL1 and SL2. The free energy of this structure is 240.2 kcal/mol compared to the structure shown in panel B, from position 1243 to 1359,
with free energy of 233.9 kcal/mol calculated by M-fold version 3.0 using standardized parameters (36).
5643
 o
n
 N
ovem
ber 12, 2015 by University of Queensland Library
http://jvi.asm.org/
D
ow
nloaded from
 
119, 121/139, 141, and 142, that maintained TAR RNA
structure (TAR6) (Fig. 1). Supernatant from each cell line was
subjected to ultracentrifugation through a 20% sucrose cush-
ion. The virus pellets were resuspended in serum-free RPMI
1640 medium, and their p24 Ag contents and total RT activi-
ties were measured. More than 90% of the p24 Ag present in
culture supernatants was recovered from the pellets, and RT
activity was detected only in the virus pellets (data not shown).
The ratio of p24 Ag concentration to total RT activity was
calculated for each virus stock, and the p24/total RT ratios
observed in TAR mutant and wild-type virus stocks fell within
the same range (Table 1).
Jurkat cells were infected with equivalent amounts of each
virus for 2 h, after which the virus was removed. Infected and
mock-infected cells were cultured for 3 weeks, and the culture
supernatant was sampled twice weekly. The peak amount of
p24 Ag produced by each infection was used as a measure of
the replication potential of each virus and was expressed rel-
ative to the wild-type level (Table 1). TAR6 virus, which had an
intact TAR-like RNA stem-loop structure, replicated at wild-
type levels as previously observed. In contrast, the TAR1,
TAR2, and TAR3 mutants failed to replicate at all, while
TAR4 and TAR5 replicated at very low levels. These results
are consistent with previous reports on the effect of TAR
mutations on virus replication kinetics (15, 25). The previously
observed capacity of these TAR structures to support activa-
tion of HIV-1 gene expression by Tat correlated with both the
replication kinetics observed in Jurkat cells and the levels of
virus made by stably transfected 293 cells (4, 13, 14, 16).
An intact upper TAR structure is required for natural en-
dogenous reverse transcription. We used PCR to measure the
amounts of negative strong-stop DNA synthesized by each of
these viruses in natural endogenous reverse transcription
(NERT) assays (32, 35), and we expressed the NERT capacity
of each virus relative to that of the wild type. Consistent with
previous results in a cell infection assay system, the TAR1 and
TAR6 mutants produced 63 and 71%, respectively, of wild-
type amounts of negative strong-stop DNA in NERT assays
(Fig. 2). In contrast, the TAR2, TAR3, TAR4, and TAR5
mutants displayed only 10 to 17% of wild-type NERT capacity
(Fig. 2). It is therefore apparent that deletion of sequences
from position 122 to 124 had only minor effects on reverse
transcription, while transposition of the bulge (TAR3, nt 137
to 138) resulted in defective reverse transcription. These
NERT results confirmed that the stem structure, but not the
primary sequence, of TAR from position 118 to 121 and 139
to 142 is required for optimal HIV-1 reverse transcription
initiation. TAR5, which has a symmetrical internal loop at
119/141, was also defective for negative strong-stop DNA
synthesis in NERT assays. Finally, the TAR4 mutation, which,
according to stem energy calculations (36), favors an alternate
structure over a less stable TAR-like RNA conformation, also
reduced negative strong-stop DNA synthesis relative to that of
the wild type.
An intact upper TAR structure is required for efficient pack-
aging of HIV-1 genomic RNA. A previous analysis of HIV-1
TAR mutants (18) failed to detect significant defects in RNA
packaging, but that study did not eliminate the possibility that
defects in RNA packaging resulted in the encapsidation of
spliced HIV-1 RNA species. Therefore, we performed both
RT-PCR and RNA protection assays to quantitate and char-
acterize virion RNA content in viruses with mutated TAR
sequences. The RT-PCR strategy was similar to a previously
described strategy (Fig. 3). Briefly, an in vitro-transcribed
HIV-1 RNA with an internal 71-nt deletion was used as an
internal control in the RT-PCR assay. Partially purified virus
containing 100 ng of p24 Ag was lysed in Trizol solution, and
5 ng of synthetic internal control RNA was added. First-strand
cDNA synthesis was performed in separate reactions using
primer A, which hybridized to both spliced and unspliced
RNA, and primer B, which hybridized only to unspliced RNA.
The cDNA products were analyzed by PCR using primers
specific for HIV-1 or internal control sequences. The PCR
products were separated by polyacrylamide gel electrophoresis
and then visualized and quantitated with a Molecular Dynam-
ics PhosphorImager. As shown in Fig. 4, similar levels of
HIV-1 genomic RNA were measured by RT-PCR in the
TAR1, TAR5, TAR6, and wild-type viruses. RNA packaging
in the TAR2 and TAR4 viruses was reduced to approximately
55% and approximately 10%, respectively, of the wild-type
level. The overall reduction in copy numbers detected in first-
strand reactions containing primer B, compared to primer A,
was due to the lower efficiency of primer B in first-strand
synthesis and was consistent between HIV-1-specific and in-
ternal control primers.
RNase protection assays were performed on virion RNA
and cellular RNA from the corresponding 293 stable cell lines,
using a 550-bp antisense RNA probe that spanned the 59 major
splice donor site. Full-length HIV-1 genomic RNA overlaps
with 363 nt of the probe, while spliced HIV-1 RNA overlaps
with only 189 bp. Virion RNA isolated from partially purified
virus containing 100 ng of p24 Ag, or 10 mg of total cellular
RNA isolated from stable 293 cell lines, was incubated with the
radiolabeled antisense RNA probe. As shown in Fig. 5, both
genomic and spliced HIV-1 RNA species were detected in cell
lines producing TAR5, TAR4, and wild-type viruses. The ra-
tios of full-length to spliced RNA were 0.82, 0.51, and 0.83 in
TAR5, TAR4, and wild-type virus, respectively. These ratios
are similar to the RNA ratios in wild-type and TAR mutant
viruses reported by Clever et al. (8). Virion RNA from TAR5,
TAR4, and wild-type virus protected an RNA fragment indic-
ative of full-length genomic RNA, but little if any spliced RNA
was detected. In this and other similar RNase protection as-
says, the RNA packaging efficiency of the TAR5 mutant
ranged from 50 to 60% of the wild-type level, compared to the
value of 80% obtained from the RT-PCR assay. The RNA
packaging efficiency of TAR4 ranged from 8 to 11% of the
wild-type level, consistent with the RT-PCR assay results.
The relative reverse transcription efficiency of each TAR
RNA mutant was calculated as the percentage of wild-type
NERT activity divided by the percentage of wild-type RNA
packaging level (Fig. 6). This analysis revealed that the NERT
defect observed in the TAR4 virus could be attributed almost
entirely to decreased RNA packaging, while the TAR1 and
TAR6 viruses both had relative reverse transcription efficien-
cies which were reduced by less than onefold, which was con-
sistent with previous results (18, 20). The TAR2, TAR3, and
TAR5 viruses were all defective for reverse transcription; the
TAR3 mutant had a sevenfold defect compared to wild-type
virus. The reverse transcription defects associated with TAR5
were lower in NERT assays than previously reported for cell
infection assays (13) and were partly due to reduced packaging
efficiency.
DISCUSSION
In this study we confirmed that TAR is required for efficient
HIV-1 reverse transcription. The upper stem-loop from posi-
tion 118 to 142 is required for this function of TAR, but
reverse transcription is not strictly dependent on the bulge
sequences from position 122 to 124, since deletion of these
sequences had no effect. However, reverse transcription was
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down regulated when the bulge was either transposed to the
opposite side of the stem or shifted by an internal deletion,
indicating that the role of TAR in reverse transcription is
dependent on its secondary structure. The mechanism by
which TAR exerts its effect remains unknown, but it may in-
volve the binding of viral or cellular proteins that facilitate
reverse transcription. Alternatively, TAR may form alternative
RNA structures that stabilize the reverse transcription com-
plex. The TAR RNA upper stem-loop structure is the binding
site for the HIV-1 Tat protein and cellular protein complexes
that contain the RNA polymerase II large subunit, Trp-185,
and Tat-cyclin-T1 (33, 34). The binding events involving these
proteins share a common dependence upon single-stranded
regions of the loop and.or bulge regions of TAR. The binding
of protein to RNA is commonly accompanied by a conforma-
tional change in RNA structure. For example, crystal structure
analysis of the anticodon loops of tRNAs complexed with the
appropriate aminoacyl-tRNA synthetases showed that protein
interactions facilitate unstacking of anticodon sequences, al-
lowing them to bind in separate recognition pockets in the
RNA structure (10). In TAR RNA, the three-nucleotide bulge
causes a distortion in the RNA duplex which makes the major
groove accessible, and binding of ligands to this region results
in the formation of a triple base pair between U23 and A27-
U38 that restores TAR RNA to an A-form-like duplex (1, 7,
30). It is intriguing that the TAR bulge deletion mutation, an
A-form RNA duplex structure, was the only bulge mutation
that supported high levels of reverse transcription. It is possi-
ble that Tat or another TAR binding protein may induce a
similar conformational change in TAR structure and that this
conformational change favors efficient reverse transcription. In
a separate study, Tat was shown to be required for efficient
early reverse transcription in the absence of obvious biochem-
ical defects in the virions (17, 32), but numerous attempts to
detect Tat in purified HIV-1 have been unsuccessful. Studies
are under way in our laboratory to determine whether other
viral proteins such as RT and Ncp7 specifically bind to the
TAR element.
The multiple functions associated with TAR include tran-
scription, translation, genomic RNA packaging, and reverse
transcription. Some of these functions are at least partially
controlled by complex RNA structures. For example, packag-
ing depends on the so-called psi sequences, which include the
stem-loop structures SL1, SL2, and SL4 (Fig. 7A) (3, 9, 19, 27),
and reverse transcription requires RNA interactions between
the primer binding site and flanking sequences that bind the
anticodon loop of tRNA3
Lys (22, 36, 37). Some earlier studies of
TAR mutations used gross clustered mutations that greatly
altered TAR structure. For example, a mutation called
Xho110 destabilized TAR from position 12 to 116 and re-
duced packaging efficiency by more than 90% (11). However,
these large mutations may allow alternative Watson-Crick base
pairing with nearby sequences, and this may interfere with
other natural RNA structures. Computer analysis indicates
that Xho110 sequences have a strong potential to base pair
with nearby sequences within SL1, which could cause marked
changes in the RNA structures of SL1 and SL2 (Fig. 7B and
C). Our results confirm that TAR plays a role in packaging,
since viruses with altered TAR structures have packaging de-
fects. In this study and others, viruses that formed non-TAR-
like structures, or which destabilized the lower stem structure,
were associated with packaging defects of 90% or greater (8,
11, 20, 28). Mutations in TAR that destabilized portions of the
lower stem without disturbing other structural elements greatly
reduced RNA packaging, and second-site mutations that re-
stored the stem base pairing also restored RNA packaging.
These observations indicate that structure rather than primary
RNA sequence is important for this function of TAR. The
seminal observations that distinct pools of genomic RNA traf-
fic to either translation or packaging processes (26), that TAR
RNA inhibits translation (6, 31), and that the TAR lower stem
region contributes to an efficient packaging signal (8, 11, 20) all
suggest that specific features of the TAR lower stem are one
determinant of RNA packaging and translation pathways that
is codependent upon other RNA structures or RNA binding
proteins.
Our results provide evidence that the TAR upper stem
structure is also important for RNA packaging, since the
TAR4 mutant, which has an altered upper stem-loop structure
but a conserved lower stem mutation, was defective for RNA
packaging. However, not all of the TAR mutations fit this
model. For example, a TAR deletion from position 134 to
137 would be expected to form an alternative RNA structure,
yet genomic RNA carrying this deletion was efficiently pack-
aged into virions (20). At least a partial explanation for this
may lie in the different methods which have been used to
generate virus in different studies. Several studies produced
virus by transient expression from proviral plasmids, and in
some cases these plasmids carried a simian virus 40 origin of
replication. Transfection of these plasmids into either COS or
293T cells, both of which make simian virus 40 large T antigen,
results in amplification of the plasmid and synthesis of large
quantities of viral transcripts. In contrast, the present study
used isolated cell lines with stably integrated proviral con-
structs, resulting in levels of virus production more nearly
approximating those in a natural infection. The impact of this
technical difference is not known and requires further analysis.
Further study is also required to identify the specific features
of TAR that support reverse transcription and genomic RNA
packaging. Attempts to identify potential cofactors of reverse
transcription are in progress in our laboratory.
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